Stock Earnings
Investing in Altimmune Inc (ALT) Is Getting More Attractive
Altimmune Inc’s recently made public that its Director Sohn Catherine A. acquired Company’s shares for reported $5784.0 on Mar 17
Menu
Altimmune Inc’s recently made public that its Director Sohn Catherine A. acquired Company’s shares for reported $5784.0 on Mar 17
The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or
Altimmune Inc’s filing revealed that its Director Sohn Catherine A. acquired Company’s shares for reported $5784.0 on Mar 17 ’25.
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Altimmune Inc’s recently made public that its Director Sohn Catherine A. acquired Company’s shares for reported $5784.0 on Mar 17
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Altimmune Inc’s recently made public that its Director Sohn Catherine A. acquired Company’s shares for reported $5784.0 on Mar 17
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Pfizer Inc (PFE) was down -0.45 percent to $37.27 whereas it’s German partner BioNTech SE (BNTX) fell by 3.10 percent